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Management of Patients Undergoing Non-cardiac
Vascular Surgery. Eur J Vasc Endovasc Surg 2007;34:
625e631’’.The comprehensive review by Howell and Vohra
describes several strategies for the optimisation of
the perioperative management of patients undergoing
non-cardiac vascular surgery.1 An issue which could
possibly be addressed more extensively is statin
therapy.
Statin treatment has been suggested to improveperi-
operative, as well as long-term, morbidity and mortal-
ity rates in patients undergoing non-cardiac vascular
surgery.2 Statins are also associated with fewer cardio-
vascular complications and a shorter length of in-
hospital stay compared with non-users.2
Furthermore, statins exhibit multiple non-lipid
related properties, including anti-inflammatory and
anti-atherosclerotic actions, in addition to reducing car-
diovascular events.2,3 Since vascular patients usually
have arterial disease affecting >1 territory,1e3 statins
should be used to manage atherosclerosis and exert
their pleiotropic effects in other vascular beds as well.
The need for randomised controlled trials is un-
questionable.1e3 However, ethical restrictions due to
the reported benefits of statin treatment may render
not possible the performance of such trials. Current
evidence suggests that statins are safe and cost-
effective agents that should be employed in the med-
ical and surgical management of vascular patients.2,3
While expecting the results of randomised trials, it
seems reasonable to include statins in the periopera-
tive management of these patients.
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Will There Ever be a Randomised Control Trial
(RCT) Studying the Effects of Statins on Patients
Undergoing Non-cardiac Vascular Surgery (NCVS)?We thank Dr. Paraskevas for his response. As he notes,
statin therapy appears to improve perioperative and
long-term morbidity and mortality in patients under-
going NCVS.1 A large RCT is needed to confirm these
findings. Many patients who would be candidates for
such a trial have a primary or secondary indication for
statin administration2 making it difficult to randomise
them. In addition some feel that a shift in emphasis
from risk stratification to risk modification with ther-
apeutic interventions, including statin administration
should be adopted.3
A major concern of perioperative statin therapy has
been the risk of elevated serum transaminases, myopa-
thy and rhabdomyolysis. While elevated transaminases
are frequently observed, there is little evidence that
statins cause progressive liver disease.4 However the
risk of myopathy and rhabdomyolysis are increased
with commonly used concomitant drugs including
macrolideantibiotics,digoxinandwarfarin.4 Inaddition
the risk of these potentially fatal complications maybe
further potentiated by dehydration in the perioperative
period.r Surgery. Published by Elsevier Ltd. All rights reserved.
380 CorrespondenceIt is unclear whether an RCT studying the effects
of statins on patients undergoing NCVS will occur
even though the need for one is probably justified.
However we also feel it is reasonable to include
statins in the perioperative management of these
patients.
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